Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315). 26. Oktober 2018 Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Bernhardt, C., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Rittmeyer, A., Bischoff, H., Waller, C., Sebastian, M., Thomas, M., 2018. Ann Oncol, 43rd ESMO Congress 29 (suppl 8)(1428P). doi:https://doi.org/10.1093/annonc/mdy292.050 Abstract Prospective real world data of an ongoing post-authorization safety study on idelalisib in patients with CLL and refractory FL. Hoechstetter, M., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Ramroth, H., Rummel, M., 2018. Oncol Res Treat 41 (suppl 4) (P534), 173. Weiterlesen Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study. Welslau, M.K., Zaiss, M., Söling, U., Untch, M., Müller, L., Lüftner, D., Meiler, J., Welt, A., Sahlmann, J., Houet, L., Runkel, E., Marschner, N.W., 2018. Weiterlesen